Lilly Reports Oct. 29 a Week After a Record Close. Its Q2 Volume Rose 60% While Prices Fell 13%.

Key Takeaways

• Eli Lilly enters the October 29 report with a powerful but changing growth mix: second-quarter revenue rose 48% as volume increased 60%, yet realized prices fell 13%, making the durability of volume growth more important than another headline earnings beat.
• Kavout’s scores show a strong trend but less confirmation at the current price: the composite score is 64, the technical rating is 58, and the moving-average score is 83 as shares sit near a record close.
• Deal-related acquired-R&D charges have made Q3 EPS consensus unreliable (published figures range from $5.70 to $6.67), so revenue against about $22.6 billion, realized price and any guidance move toward the roughly $88.7 billion consensus are the cleaner tests.

Lilly’s Growth Is Now a Volume-versus-Price Equation

Eli Lilly and Company (LLY) is no longer presenting investors with a simple high-growth pharmaceutical story. The central question before the October 29 report is whether rapidly expanding patient volume can continue to outrun falling realized prices.

That tension was visible in the second quarter. Revenue reached $22.974 billion, up 48% from the prior-year quarter, while total volume increased 60% and realized price declined 13%. The arithmetic is the point: Lilly sold substantially more medicine, but each unit generated less revenue on average. The company still produced exceptional top-line growth because volume overwhelmed the price concession, but the mix leaves less room for execution mistakes.

The pressure was especially clear outside the United States. International revenue increased 80%, driven by a 113% volume increase, while realized price fell 36%. Much of that decline came after Mounjaro entered China’s national reimbursement list, which expanded access but reduced the price Lilly received per treatment.

In the United States, the reported price decline was smaller, but the underlying picture is not frictionless. U.S. revenue rose 33% on 37% volume growth and a 3% reported price decline. Excluding adjustments related to estimated rebates, the company characterized the U.S. price decline at approximately 9%.

That makes the October report a quality-of-growth test. If volume remains strong while U.S. price pressure stabilizes, the second-quarter pattern can support a durable earnings expansion. If volume growth slows while price concessions widen, the market may begin treating the 48% revenue increase as a peak-growth comparison rather than a sustainable run rate.

The key distinction for investors is between demand and monetization. Lilly appears to be winning on demand, but the report must show whether that demand can be converted into revenue and profit without progressively larger price concessions.

Mounjaro Is Carrying the Story, but the Mix Is Broadening

Mounjaro remains the most important near-term engine. Second-quarter sales reached $9.943 billion, up 91% from the prior year. U.S. sales increased 45%, while sales outside the United States rose 172%. That international growth explains why the price-volume debate matters so much: the fastest expansion is also occurring in markets where reimbursement decisions can sharply change realized price.

Zepbound adds a second large growth stream. Second-quarter revenue was $4.928 billion, up 46%. Taken together, Mounjaro and Zepbound generated roughly $14.9 billion in the quarter, which is about two-thirds of total revenue. That concentration is not automatically a weakness; it shows that Lilly has products with enormous commercial traction. But it also means pricing, reimbursement, and competitive developments in obesity and diabetes drugs will have an outsized effect on the whole company.

The emerging signal is that Lilly is trying to widen the product funnel before the existing products mature. Foundayo, its oral GLP-1, contributed $98 million in its launch quarter. That figure is too early to judge as a normalized contribution, but the commercial direction matters. Management said late-July volume was almost doubling from a month earlier, and a European regulatory committee recommended approval for weight management and type 2 diabetes on October 16.

The stock gained 3.5% on October 20 after that recommendation, moving from $1,240.34 to $1,283.66. That reaction shows how investors are valuing the option on an oral product, not merely the revenue already reported. An oral formulation could broaden adoption and provide a new way to defend the franchise, but the October 29 report will offer only an early read on whether the launch is becoming material.

The report therefore needs to show more than whether Mounjaro and Zepbound beat a quarterly estimate. Investors need evidence that the product mix is broadening and that new volume is not being purchased at an economically damaging price.

The Guidance Raise Was Strong, but Its Quality Was Uneven

Lilly raised 2026 revenue guidance from $82 billion to $85 billion at the low end and from $85 billion to $87 billion at the high end. It also raised its performance-margin range from 47.0% to 48.5% to 49.0% to 50.5%.

That is a meaningful operating signal. Higher revenue and a higher performance-margin range imply that management still sees enough scale and cost absorption to support better profitability even while prices are under pressure. Non-GAAP gross margin was 86.3% in the second quarter, up from 85.0% a year earlier, so the price decline has not yet translated into a deterioration in reported gross economics.

But the first half contained items that make the guidance raise less clean than the headline suggests. Lilly said the first half benefited from sales-based milestones and adjustments for rebates and discounts. The second quarter also included a $250 million sales-based milestone tied to Jardiance outside the United States.

Those items do not invalidate the guidance. They do, however, reduce the amount of confidence investors should place in a straightforward extrapolation from first-half earnings. The company’s own disclosure says part of the period’s strength came from factors that may not recur in the same form.

The same issue applies to earnings per share. Second-quarter non-GAAP EPS was $8.38, up 33% from $6.31, but that result came after $3.03 per share of acquired in-process research and development charges. Lilly includes those acquired-development charges in non-GAAP EPS, meaning acquisitions can directly depress the reported figure even when the underlying commercial business is improving.

That accounting treatment is especially relevant because deal activity remained high. Lilly completed several acquisitions in the second quarter and added further infectious-disease and vaccine transactions in the third quarter, while agreeing to acquire AtaiBeckley for cash plus a contingent value right. The third-quarter acquired-development charge has not been disclosed, so the earnings-per-share comparison cannot be cleanly modeled in advance.

The practical implication is straightforward: revenue, volume, realized price, and operating margin deserve more weight than the raw EPS beat or miss. An EPS result distorted by acquisition charges could obscure a healthy quarter or make a strong quarter look weaker than it is.

The Market Is Rewarding the Trend, Not Ignoring the Price

LLY closed at $1,306.69 on October 22, a record closing price, before retreating to $1,273.46 on October 23. At the latest close, the stock was still 18.5% above its year-end level and 7.7% above its level roughly one month earlier.

Kavout’s scores capture both sides of that move. The composite score is 64, indicating a favorable overall setup, while the technical rating is lower at 58. The moving-average score is much stronger at 83. Read together, those figures say that the underlying trend is clearly positive, but the current price is not receiving the same degree of confirmation from every technical lens.

That spread matters. A strong moving-average score usually reflects sustained price leadership: the stock remains above important trend lines and has advanced enough to keep those averages rising. The lower technical rating suggests that shorter-term conditions are less clean. After the October 20 surge and the record close two sessions later, some of the good news appears to be reflected in price.

The latest quote sits about 7% above the 50-day average of $1,186.60 and roughly 17% above the 200-day average of $1,084.94. Those gaps confirm the strength of the trend, but they also mean the stock goes into the report after a fast advance, with more good news already reflected in the price.

The price history around earnings adds another layer. Lilly gained 4.9% on the August report and had also gained on the prior three reported quarters, but it fell 14.1% in August 2025 and 11.7% in May 2025. The lesson is not that the next reaction will be negative. It is that earnings-day moves have been large in both directions.

A strong long-term trend does not eliminate event risk; it raises the stakes of the report.

Eli Lilly daily chart with technical signals, through the Oct 23 close

The Bull Case Has More Than One Catalyst

Foundayo’s regulatory progress is only one part of the forward setup. Lilly also reported positive Phase 3 results for retatrutide across additional obesity-related indications, with a U.S. biologics filing planned for the first quarter of 2027. That timeline is outside the immediate earnings window, but it gives investors another potential growth leg beyond the current injectable products.

The company is also expanding access through coverage developments for Foundayo and Zepbound. Broader coverage can support volume, although it may also require pricing concessions. That is precisely why the volume and price figures must be read together rather than treated as separate good-news items.

The latest pipeline news extends beyond metabolic disease. Lilly presented first clinical data for its next-generation ovarian-cancer antibody-drug conjugate at a major oncology meeting on October 24, while also highlighting first-line lung-cancer data for olomorasib. These programs are not yet substitutes for the obesity franchise, but they add breadth to the long-term commercial base and give the market additional reasons to value Lilly as a platform rather than a one-category company.

Manufacturing investment provides another supporting signal. Lilly broke ground on October 22 on a Richmond facility for next-generation cancer medicines, part of its build-out of 10 new U.S. sites since 2020. The announcement is strategic rather than immediately earnings-accretive, but it indicates that management is building capacity around a broader future portfolio.

The risk is that investors may capitalize every pipeline advance before the existing franchise proves it can maintain economic quality. The October 29 report cannot settle the long-term value of retatrutide or the oncology programs. It can, however, show whether the cash-generating metabolic franchise is financing that expansion from operating strength rather than from increasingly aggressive price and deal assumptions.

Consensus Likes the Stock, but the Earnings Bar Is Moving

Analyst sentiment is strongly positive: 33 analysts rate LLY a buy, compared with 9 holds and 3 sells. The consensus price target is $1,355.25, only about 6.4% above the latest close. The median target is higher at $1,380.50, but the full range stretches from $940 to $1,500.

That dispersion is important. The consensus target indicates additional upside, but the range shows that analysts disagree materially about how much of Lilly’s future growth is already reflected in the stock. The target is therefore useful as a reference point, not as a precise valuation anchor.

Longer-term estimates remain ambitious. Analysts project 2029 revenue of $124.5 billion and 2030 revenue of $134.4 billion. Those figures imply that the market expects Lilly’s growth to continue well beyond the current product cycle, supported by the oral GLP-1, retatrutide, and pipeline expansion.

Yet the near-term EPS bar has become less reliable. One estimate places third-quarter EPS at $5.70, while another published consensus is $6.67, and the latter had reportedly fallen from $9.87 over the prior month as analysts incorporated acquisition-related charges. That is too wide a change in expectations to treat a small EPS beat or miss as a definitive read on the business.

The revenue comparison is cleaner. A third-quarter revenue estimate near $22.6 billion can be evaluated against product volume, realized price, and guidance. If Lilly delivers revenue in line with or above that level while maintaining its margin range, investors can reasonably conclude that the volume engine is still absorbing price pressure. If revenue is weaker despite strong unit growth, pricing and reimbursement will move to the center of the thesis.

October 29 Should Be Read Through a Five-Point Scorecard

The report’s most valuable information will not necessarily be the first line of the release. Investors should focus on five linked questions.

First, are Mounjaro and Zepbound still producing strong volume growth without a further deterioration in realized price? The second quarter proved that volume can overpower price declines, but it did not prove that the same relationship can persist indefinitely.

Second, what happens to U.S. price after removing rebate-estimate adjustments? The reported 3% U.S. decline understates the underlying pressure if the approximate 9% adjusted figure is the better economic measure. A stabilization would be more important than another isolated volume surprise.

Third, is Foundayo beginning to move from launch evidence toward a meaningful commercial contributor? Its $98 million starting point is small relative to total company revenue, so the value of the October update lies in the pace of adoption and the quality of access, not in the absolute quarter alone.

Fourth, does management raise 2026 revenue guidance toward the roughly $88.7 billion analyst expectation? Lilly’s current range tops out at $87 billion. Moving closer to that outside expectation would validate demand; maintaining the range could signal that management remains cautious about price, reimbursement, or one-time first-half benefits.

Fifth, how large are the third-quarter acquired-development charges, and what does management say about future deal spending? Because the charge has not been disclosed, investors should not pre-judge the EPS outcome. The more useful question is whether business development is adding future growth at a pace that justifies its near-term accounting cost.

A sixth issue sits across all five: competitive pricing from Novo Nordisk. Novo’s newer obesity data and pricing moves could force Lilly to choose between defending share and defending price. Management’s stated intention is to more than offset price pressure with volume growth. October 29 is the next evidence check on that promise.

What the Evidence Adds Up To

The case for Lilly’s growth is strong on the evidence: 60% volume growth, Mounjaro nearly doubling, gross margin above 86%, guidance raised twice, an oral GLP-1 moving toward EU approval, and a retatrutide filing planned for early 2027. The case for caution is also on the record: realized prices fell 13%, U.S. price fell about 9% excluding rebate adjustments, the company itself said first-half results were helped by milestones and rebate adjustments, Novo Nordisk is pushing on price, and the stock has fallen 11% to 14% on two of its last six report days.

The stock goes into October 29 near that balance point. It closed at $1,273.46, 2.5% below the October 22 record, about 7% above the $1,186.60 50-day average and roughly 6% below the $1,355.25 consensus target. The October 13 close of $1,166.51 marks where the latest leg of the advance began.

The report will show whether the volume engine is still outrunning price. Watch U.S. realized price excluding adjustments, Mounjaro and Zepbound volume, Foundayo’s second full quarter, the size of the third-quarter acquired-R&D charge, and whether management moves the $85 billion to $87 billion revenue range toward the market’s expectation.

For Lilly, the next report is not simply an EPS event; it is the point at which exceptional volume growth must prove it can continue paying for weaker prices.

---

Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.